ALK FISH阳性比例与克唑替尼疗效在三项前瞻性ALK阳性NSCLC研究中的相关性
该研究汇总三项前瞻性试验数据,评估ALK FISH阳性细胞百分比与克唑替尼疗效的关系。结果显示,在≥15%至≥20%的ALK阳性范围内,客观缓解率相似,且治疗与ALK阳性百分比的交互作用无统计学意义,支持15%作为阳性界值的临床实用性。
要点
- 在ALK阳性NSCLC患者中,克唑替尼的获益覆盖ALK FISH阳性细胞百分比的全范围,支持15%界值。
- ALK阳性且接受克唑替尼治疗的患者中,≥20%阳性细胞的客观缓解率为56%,≥15%者为55%,15%-19%者为38%。
- 治疗与ALK阳性百分比之间的交互作用检验无统计学意义(客观缓解P=0.054,PFS P=0.17)。
核心结论
- ALK阳性NSCLC患者从克唑替尼治疗中获益,不受ALK FISH阳性细胞百分比的显著影响,支持15%作为阳性界值的临床实用性。
研究设计与样本
- 汇总三项前瞻性试验(一项单臂试验和两项随机对照化疗试验)的数据,纳入经Vysis ALK Break Apart FISH检测且ALK阳性(≥15%阳性细胞)的NSCLC患者。
主要发现
- 在11 081例筛查患者中,1958例(18%)为ALK阳性,7512例(68%)为ALK阴性,1540例(14%)为无信息结果。
- ALK阳性患者的中位ALK阳性细胞百分比为58%,ALK阴性患者为2%;ALK阳性患者中5%的阳性细胞百分比为15%-19%,ALK阴性患者中2%的阳性细胞百分比为10%-14%。
- ALK阳性且接受克唑替尼治疗的患者中,≥20%阳性细胞的客观缓解率为56%(n=700/1246),≥15%者为55%(n=725/1312),15%-19%者为38%(n=25/66)。
- 作为连续变量,较高的ALK阳性细胞百分比估计与克唑替尼和化疗之间更大的客观缓解和PFS差异相关,但治疗与ALK阳性细胞百分比的交互作用检验无统计学意义(客观缓解P=0.054;PFS P=0.17)。
关键数值与推荐
- ALK阳性定义为Vysis ALK Break Apart FISH检测显示≥15%的ALK阳性细胞。
- ALK阳性且接受克唑替尼治疗的患者中,≥20%阳性细胞的客观缓解率为56%(n=700/1246),≥15%者为55%(n=725/1312),15%-19%者为38%(n=25/66)。
临床怎么用
- 对于经FISH检测确认ALK阳性(≥15%阳性细胞)的NSCLC患者,均可考虑使用克唑替尼治疗,无需因阳性百分比接近界值而排除获益可能。
局限性
- 接近15%界值的患者数量较少,需进一步研究,因技术或生物学原因可能导致ALK状态误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship between the percentage of ALK-positive cells by fluorescence in situ hybridization (FISH)-particularly near the cut-off defining positive status-and clinical outcomes have been limited by small sample sizes. PATIENTS AND METHODS: Data were pooled from three large prospective trials (one single-arm and two randomized versus chemotherapy) of crizotinib in patients with ALK-positive NSCLC determined by Vysis ALK Break Apart FISH using a cut-off of ≥15% ALK-positive cells. Logistic regression and proportional hazards regression analyses were used to explore the association of percent ALK-positive cells with objective response and progression-free survival (PFS), respectively. RESULTS: Of 11 081 screened patients, 1958 (18%) were ALK positive, 7512 (68%) were ALK negative, and 1540 (14%) were uninformative. Median percentage of ALK-positive cells was 58% in ALK-positive patients and 2% in ALK-negative patients. Of ALK-positive patients, 5% had 15%-19% ALK-positive cells; of ALK-negative patients, 2% had 10%-14% ALK-positive cells. Objective response rate for ALK-positive, crizotinib-treated patients with ≥20% ALK-positive cells was 56% (n = 700/1246), 55% (n = 725/1312) for those with ≥15% ALK-positive cells, and 38% for those with 15%-19% ALK-positive cells (n = 25/66). As a continuous variable, higher percentages of ALK-positive cells were estimated to be associated with larger differences in objective response and PFS between crizotinib and chemotherapy; however, tests for interaction between treatment and percentage of ALK-positive cells were not significant (objective response, P = 0.054; PFS, P = 0.17). CONCLUSIONS: Patients with ALK-positive NSCLC benefit from treatment with crizotinib across the full range of percentage of ALK-positive cells, supporting the clinical utility of the 15% cut-off. The small number of patients with scores near the cut-off warrant additional study given the potential for misclassification of ALK status due to technical or biologic reasons.
引用
- Soria JC, Ho SN, Varella-Garcia M, et al. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018. PMID: 30010763. doi:10.1093/annonc/mdy242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。